Founders stepping aside for outside CEOs and then returning as CEO later on is quite a trope in the tech world, and Daniel ...

UiPath focuses on agentic automation, boasts a large ARR base, and has high gross margins. Click here to read why PATH stock ...

Despite a 20% stock decline, we maintain a bullish view on UiPath due to its strategic pivot to Agentic AI and strong ...

UiPath announced the launch of its generative AI-based UiPath Medical Record Summarization agent, powered by Google Cloud ...

Both APP and PATH are technology companies leveraging artificial intelligence to enhance their platforms. Which one is a ...

Learn more about whether Asana, Inc. or UiPath Inc. is a better investment based on AAII's A+ Investor grades, which compare ...

UiPath shares rise on launch of generative AI-based UiPath Medical Record Summarization agent at Google Cloud Next 2025.

Cathie Wood's Ark Invest sold shares in UiPath, Prime Medicine, and Repare Therapeutics, with notable gains and losses.

Today, I’m talking with Daniel Dines, the cofounder and, once again, the CEO of UiPath, a software company that specializes in something called robotic process automation (RPA). We’ve been ...

UiPath (PATH) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Learn more about whether UiPath Inc. or Qualys, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

UiPath (NYSE:PATH) recently launched its AI-based Medical Record Summarization Agent at the Google Cloud Next 2025 event, emphasizing efficiency and cost savings in healthcare. Despite these promising ...